<DOC>
	<DOCNO>NCT02994927</DOCNO>
	<brief_summary>The aim trial ass safety efficacy orally-administered , selective complement C5a receptor inhibitor CCX168 ( avacopan ) induce sustain remission patient anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis ( AAV ) .</brief_summary>
	<brief_title>A Phase 3 Clinical Trial CCX168 ( Avacopan ) Patients With ANCA-Associated Vasculitis</brief_title>
	<detailed_description>Complement 5a receptor C5aR ( CD88 ) involve pathogenesis anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis . This randomized , double-blind , placebo-controlled Phase 3 study evaluate safety efficacy orally-administered , selective C5aR inhibitor CCX168 ( avacopan ) induce sustain remission patient anti-neutrophil cytoplasmic antibody ( ANCA ) -associated vasculitis ( AAV ) treat concomitantly Rituximab Cyclophosphamide/Azathioprine .</detailed_description>
	<mesh_term>Vasculitis</mesh_term>
	<mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Azathioprine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<criteria>Clinical diagnosis granulomatosis polyangiitis ( Wegener 's ) microscopic polyangiitis Male female subject , age least 18 year , newlydiagnosed relapsed AAV treatment cyclophosphamide rituximab need ; approve Regulatory Agencies , adolescent ( 1217 year old ) may enrol Use adequate contraception Positive test antiPR3 antiMPO At least 1 major item , least 3 nonmajor item , least 2 renal item proteinuria hematuria BVAS Estimated glomerular filtration rate ≥15 mL/minute/1.73 m^2 screen Pregnant breastfeed Alveolar hemorrhage require pulmonary ventilation support screen Any known multisystem autoimmune disease Required dialysis plasma exchange within 12 week prior screen Have kidney transplant Received cyclophosphamide within 12 week prior screen ; azathioprine , mycophenolate mofetil methotrexate time screening , drug must withdraw prior receive cyclophosphamide rituximab dose Day 1 Received intravenous glucocorticoid , &gt; 3000 mg methylprednisolone equivalent , within 4 week prior screen Have take oral daily dose glucocorticoid 10 mg prednisoneequivalent 6 week continuously prior screen Received rituximab Bcell antibody within 52 week screen 26 week provide B cell reconstitution occur ( i.e. , CD19 count &gt; 0.01x10^9/L ) ; receive antiTNF treatment , abatacept , alemtuzumab , IVIg , belimumab , tocilizumab , eculizumab within 12 week prior screen For patient schedule receive cyclophosphamide treatment , urinary outflow obstruction , active infection ( especially varicella zoster infection ) , platelet count &lt; 50,000/μL start dosing Participated previously CCX168 study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>ANCA-associated vasculitis</keyword>
	<keyword>complement</keyword>
	<keyword>vasculitis</keyword>
	<keyword>C5aR</keyword>
	<keyword>avacopan</keyword>
	<keyword>CCX168</keyword>
</DOC>